CliffBio
biologic

Tzield

teplizumab-mzwv

Loss of exclusivityNovember 2034projected — 12-year biologic exclusivity estimate
CompanyProvention Bio →View the full company profile on CliffBio

Drug detail

Brand nameTzield
Active ingredientteplizumab-mzwv
Strength2MG/2ML (1MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalNovember 2022
Marketing statusRx

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Tzield patent cliff — loss of exclusivity November 2034 | CliffBio